Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
Cardiovascular disease is "unacceptably" high and increasing among American adults ages 20 to 44, requiring aggressive prevention.
Read Full NewsUse of immediate-release amantadine as an add-on to levodopa reduced peak-dose dyskinesia incidence in patients with early Parkinson disease, according to results from the phase 2 PREMANDYSK trial.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 16, 2026.
The therapy also received orphan drug designation from the FDA.
Phase 3 MODIFY Shows No Significant Renal Benefit With Lucerastat in Fabry Disease
HCPLive 5 Stories in Under 5: Week of 01/11
Topical Antioxidant Serum May Be Effective in Treating Atrophic Acne Scars
1.
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer
2.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
3.
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
4.
Screening for prostate cancer: is it time to give up digital rectal examination?
5.
Personalized Breast Cancer Treatment; Insights Into HPV in Men; Exercise and Cancer
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
The Algorithmic Revolution: How AI is Reshaping Precision Oncology from Bench to Bedside
3.
A Comprehensive Guide to Living with Cutaneous T Cell Lymphoma: Tips & Strategies
4.
Exploring New Treatment Options for Hemophilia: A Journey into the Unknown
5.
Botulinum Toxins in Oncology: A New Frontier in Chronic Pain Management and Apoptosis Induction
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
3.
Dissecting Molecular differences between EGFR Exon 19 deletion and Exon 21 L858R Mutations
4.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
5.
Navigating the Complexities of Ph Negative ALL - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge